A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Clinical trial NCT01702571 · COMPLETED
Trial details
- NCT number
- NCT01702571
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-11-27
- Primary completion
- 2020-07-31
- Enrollment
- 2185
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.